Full Press Release Details
BioCopy AG and Immatics enter into a collaboration to characterize T cell receptor - peptide-HLA interactions.
IMTX
BioCopy AG and Immatics enter into a collaboration to characterize T cell receptor - peptide-HLA interactions
Key Takeaway: BioCopy AG and Immatics enter into a collaboration to characterize T cell receptor - peptide-HLA interactions
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+20%
120-day peak, hindsight
Typical move
3.9%
average across 7 past catalysts
Lead asset
IMA401
Phase 1 · Refractory Cancer